Neoantigen Cancer Vaccine Market by Neoantigen Type (Personalized Neoantigens, Shared Neoantigens), Therapeutic Target (Immune Checkpoint Blockade, Tumor Neoantigens), Vaccine Platform, Administration Route, End User - Global Forecast 2025-2032
Description
The Neoantigen Cancer Vaccine Market was valued at USD 378.66 million in 2024 and is projected to grow to USD 434.55 million in 2025, with a CAGR of 15.40%, reaching USD 1,191.14 million by 2032.
Setting the Stage for Neoantigen Cancer Vaccines Driving Personalized Immunotherapy Innovations and Enhancing Patient Prognoses with Clinical Adoption
Neoantigen cancer vaccines represent a transformative frontier in immuno-oncology, harnessing unique tumor-specific antigens to elicit potent, personalized immune responses. By capitalizing on the distinct mutational signatures of each patient’s tumor, these vaccines have begun to redefine therapeutic precision, minimizing off-target effects while amplifying anti-tumor activity.
Within this paradigm, two principal antigen classifications have emerged: personalized neoantigens, which are derived from immune escape and somatic mutations unique to individual tumors, and shared neoantigens, characterized by affinity peptides and recurrent tumor mutations that span multiple patients. The personalized approach offers unparalleled specificity, whereas the shared strategy enables broader application across defined patient cohorts.
Early clinical data underscore compelling safety profiles and promising immunogenicity, driving an expanding pipeline of candidates through various vaccine platforms. As regulatory frameworks adapt to accommodate these complex biologics, the stage is set for accelerated trial enrollment and strategic partnerships that will scale development efforts. Ultimately, neoantigen cancer vaccines stand poised to shift the oncology landscape toward truly individualized therapy.
Charting the Transformative Shifts in Neoantigen Vaccine Development Reflecting Accelerated Clinical Advances and Integration of Personalized Regimens
The development of neoantigen cancer vaccines has undergone rapid evolution, driven by technological advances in genomic sequencing and bioinformatic prediction algorithms. High-throughput next-generation sequencing now enables real-time identification of tumor-specific mutations, while machine learning models refine epitope selection to maximize T cell activation and durable immune memory.
Concurrently, breakthroughs in vaccine manufacturing-such as optimized mRNA synthesis, scalable peptide production, and precision-engineered cell platforms-have trimmed development timelines and improved consistency. The convergence of these capabilities with adaptive clinical trial designs is fostering an environment in which iterative protocol modifications can enhance efficacy endpoints and safety monitoring in near real time.
Regulatory agencies in multiple regions have signaled willingness to expedite review processes for personalized therapies, reflecting a heightened commitment to fostering innovation. As a result, strategic alliances between biotech pioneers and established pharmaceutical entities are accelerating, uniting deep clinical expertise with cutting-edge platform technologies. These transformative shifts are paving the way for neoantigen vaccines to become integral components of combination regimens and new standard-of-care paradigms.
Analyzing the Far Reaching Cumulative Impact of United States Tariffs Scheduled for 2025 on Neoantigen Vaccine Supply Chains and Pricing Dynamics
The scheduled implementation of new United States tariffs in 2025 is poised to exert material influence on the neoantigen vaccine supply chain. Essential raw materials such as peptide synthesis reagents, nucleic acid precursors, and specialized lipid reagents are predominantly sourced through cross-border supply networks, and increased duties may heighten input costs and complicate procurement timelines.
Manufacturers and contract development organizations are evaluating alternative sourcing strategies, including domestic partnerships and dual sourcing models, to mitigate exposure to elevated import tariffs. In addition, strategic inventory management and advanced demand forecasting are being refined to offset potential lead-time volatility and preserve production continuity.
While pricing pressures may emerge as tariff impacts are assimilated, adaptive pricing strategies and long-term supplier agreements will be critical to preserve margins without compromising affordability. Ultimately, the 2025 tariff adjustments will drive a recalibration of supply chain resilience and cost structures, compelling stakeholders to innovate operational frameworks and reinforce strategic supplier relationships across the vaccine manufacturing continuum.
Uncovering Key Segmentation Insights That Illuminate Patient Targeting Platform Differentiation and Delivery Pathways in Neoantigen Vaccine Markets
The neoantigen cancer vaccine market encompasses multiple layers of segmentation, each shaping product design, clinical application, and commercialization pathways. An antigen classification perspective distinguishes personalized constructs derived from immune escape mutations and somatic mutations, while shared constructs leverage affinity peptides and common tumor mutations to address broader patient populations. Therapeutically, the portfolio spans immune checkpoint blockade strategies-such as CTLA-4 inhibitors and PD-1 inhibitors-and tumor neoantigen modalities segmented into mutated and non-mutated antigens, underscoring the complementary nature of these approaches.
Platform technologies further diversify the landscape, integrating cell-based vaccines with dendritic cell and T cell formats, alongside DNA platforms built on circular DNA constructs and plasmid vaccines. Peptide-based vaccines range from long peptides to synthetic variants, while RNA-based platforms include mRNA vaccines and next-generation RNA innovations. Each platform’s inherent attributes dictate manufacturing complexity, stability profiles, and immunogenic potency.
Delivery mechanisms also play a pivotal role, extending from intradermal and subcutaneous administration to intravenous and emerging oral routes. End-user applications span cancer treatment centers, hospitals, and research institutes, each demanding tailored logistics, cold-chain capabilities, and clinical support services. Understanding these segmentation dimensions is vital to aligning development strategies with clinical and commercial imperatives.
Illuminating Critical Regional Dynamics and Healthcare Ecosystem Drivers Impacting Neoantigen Vaccine Adoption Across Americas EMEA and Asia Pacific
Regional dynamics are shaping the global deployment of neoantigen cancer vaccines, with the Americas leading in clinical trial registrations and innovation hubs. Robust investment in immuno-oncology research, coupled with regulatory frameworks that prioritize personalized medicine, has created a fertile environment for pilot programs and early-stage launches across major markets.
In Europe, Middle East and Africa, diverse regulatory landscapes and reimbursement models require sponsors to adopt nuanced market entry strategies. Harmonization efforts within the European Union are facilitating cross-border clinical studies, while bespoke national initiatives in certain Middle Eastern territories are accelerating adoption among treatment centers focused on precision oncology.
Asia-Pacific markets present a blend of established biotechnology ecosystems and burgeoning biopharmaceutical investment, particularly in regions with strong public-private partnerships and government incentives. Local manufacturing capacity expansion and collaborative clinical networks are reinforcing the region’s role as a critical node in global supply chains, further driving adoption and scaling of neoantigen vaccine solutions.
Examining Key Player Strategies and Collaborative Partnerships Driving Breakthroughs and Commercialization Efforts in Neoantigen Vaccine Research Pipelines
Leading biopharmaceutical companies and specialized biotech innovators are forging strategic alliances to propel neoantigen vaccine programs from bench to bedside. Key players are investing heavily in proprietary target prediction algorithms, advanced vector design and manufacturing scale-up, often partnering with contract development organizations to enhance production agility and cost efficiency.
Collaborations between academic research centers and industry consortia are accelerating translational research, enabling rapid validation of novel antigen candidates and delivery platforms. Mergers and acquisitions activity is also on the rise, with established pharmaceutical firms seeking to bolster immuno-oncology pipelines by integrating cutting-edge neoantigen experts and platform providers into their portfolios.
Competitive differentiation is increasingly grounded in clinical proof-of-concept data, scalable manufacturing infrastructure and robust intellectual property portfolios. Companies that secure strategic licensing agreements for proprietary adjuvants, delivery systems and bioinformatics tools will be best positioned to capture emerging opportunities and meet the diverse needs of oncologists and patients.
Empowering Industry Leaders with Actionable Recommendations to Overcome Development Hurdles Foster Collaboration and Accelerate Neoantigen Vaccine Adoption
To navigate the evolving complexities of neoantigen vaccine development, industry leaders should prioritize the integration of advanced computational modeling with high-throughput immunogenicity assays. Establishing cross-functional teams that bridge bioinformatics, process development and clinical operations will streamline candidate selection and accelerate go-to-clinic timelines.
Building resilient supply chains through strategic alliances with multiple raw material providers and contract manufacturers will mitigate the impact of regulatory shifts and trade policies. Simultaneously, engaging early with regulatory authorities to align on adaptive trial designs and quality benchmarks can reduce approval risks and facilitate scaled manufacturing readiness.
Furthermore, fostering collaborative consortia with academic and patient advocacy groups will amplify clinical trial recruitment and broaden real-world evidence generation. Proactive intellectual property strategies, including co-development agreements and technology licensing, will safeguard innovations while enabling flexible partnership models that maximize market access and patient impact.
Detailing an Integrated Research Methodology Incorporating Primary Interviews Secondary Data Triangulation and Expert Validation for Robust Neoantigen Insights
This research report integrates a multifaceted methodology to ensure depth, accuracy and industry relevance. Primary research was conducted through in-depth interviews with leading oncologists, immunologists, regulatory experts and manufacturing specialists to capture nuanced perspectives on clinical practice, developmental hurdles and future prospects.
Secondary sources including peer-reviewed journals, regulatory filings, conference proceedings and cutting-edge white papers were systematically reviewed to validate emerging trends and technological breakthroughs. Data triangulation was employed to reconcile insights from diverse inputs, enhancing the credibility of thematic analyses.
An expert validation process was undertaken, engaging advisory panels and steering committees to review preliminary findings and identify potential blind spots. This iterative approach ensures that the final deliverable reflects rigorous fact-checking, comprehensive coverage of global developments and actionable intelligence tailored to strategic decision-makers.
Concluding Strategic Imperatives and Outlook on Neoantigen Vaccine Innovations Signifying Future Growth Pathways and Collaborative Research Imperatives
The neoantigen cancer vaccine landscape is on the cusp of groundbreaking advances, driven by synergistic progress in genomics, immunology and biomanufacturing. As development pipelines mature and regulatory pathways evolve, stakeholders must remain agile, leveraging strategic partnerships and robust data analytics to translate scientific innovation into clinical benefit.
Regional adoption patterns and supply chain realignments underscore the importance of versatile operational models and proactive stakeholder engagement. Companies that effectively navigate tariff impacts, optimize manufacturing networks and tailor entry strategies across diverse markets will secure competitive advantage.
Ultimately, the strategic imperatives for neoantigen vaccine stakeholders include fostering cross-sector collaboration, accelerating clinical validation through adaptive design and fortifying intellectual property portfolios. By embracing these imperatives, organizations can position themselves to lead the next wave of personalized immunotherapy breakthroughs and deliver lifesaving treatments to patients worldwide.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Neoantigen Type
Personalized Neoantigens
Immune Escape Mutations
Somatic Mutations
Shared Neoantigens
Affinity Peptides
Common Tumor Mutations
Therapeutic Target
Immune Checkpoint Blockade
CTLA-4 Inhibitors
PD-1 Inhibitors
Tumor Neoantigens
Mutated Neoantigens
Non-Mutated Neoantigens
Vaccine Platform
Cell-Based Vaccines
Dendritic Cell Vaccines
T-Cell Vaccines
DNA-Based Vaccines
Circular DNA Platforms
Plasmid DNA Vaccines
Peptide-Based Vaccines
Long Peptides
Synthetic Peptides
RNA-Based Vaccines
mRNA Vaccines
Next-Gen RNA Platforms
Administration Route
Intradermal
Intravenous
Oral
Subcutaneous
End User
Cancer Treatment Centers
Hospitals
Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Agenus Inc.
AstraZeneca PLC
Avidea Technologies
Ayala Pharmaceuticals, Inc.
BioLineRx Ltd.
BioNTech SE
BioVaxys Technology Corp.
Brightpath Biotherapeutics Co., Ltd.
CureVac N.V.
Elicio Therapeutics Inc
F. Hoffmann-La Roche Ltd.
Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
Genocea Biosciences Inc
GenScript Biotech Corporation
Gilead Sciences, Inc.
Gritstone bio, Inc.
Immunomic Therapeutics, Inc.
ISA Pharmaceuticals B.V.
Medigene AG
Merck & Co., Inc.
Moderna, Inc.
Neophore Limited
Nouscom AG
Nykode Therapeutics ASA
OSE Immunotherapeutics
Takis S.r.l.
Note: PDF & Excel + Online Access - 1 Year
Setting the Stage for Neoantigen Cancer Vaccines Driving Personalized Immunotherapy Innovations and Enhancing Patient Prognoses with Clinical Adoption
Neoantigen cancer vaccines represent a transformative frontier in immuno-oncology, harnessing unique tumor-specific antigens to elicit potent, personalized immune responses. By capitalizing on the distinct mutational signatures of each patient’s tumor, these vaccines have begun to redefine therapeutic precision, minimizing off-target effects while amplifying anti-tumor activity.
Within this paradigm, two principal antigen classifications have emerged: personalized neoantigens, which are derived from immune escape and somatic mutations unique to individual tumors, and shared neoantigens, characterized by affinity peptides and recurrent tumor mutations that span multiple patients. The personalized approach offers unparalleled specificity, whereas the shared strategy enables broader application across defined patient cohorts.
Early clinical data underscore compelling safety profiles and promising immunogenicity, driving an expanding pipeline of candidates through various vaccine platforms. As regulatory frameworks adapt to accommodate these complex biologics, the stage is set for accelerated trial enrollment and strategic partnerships that will scale development efforts. Ultimately, neoantigen cancer vaccines stand poised to shift the oncology landscape toward truly individualized therapy.
Charting the Transformative Shifts in Neoantigen Vaccine Development Reflecting Accelerated Clinical Advances and Integration of Personalized Regimens
The development of neoantigen cancer vaccines has undergone rapid evolution, driven by technological advances in genomic sequencing and bioinformatic prediction algorithms. High-throughput next-generation sequencing now enables real-time identification of tumor-specific mutations, while machine learning models refine epitope selection to maximize T cell activation and durable immune memory.
Concurrently, breakthroughs in vaccine manufacturing-such as optimized mRNA synthesis, scalable peptide production, and precision-engineered cell platforms-have trimmed development timelines and improved consistency. The convergence of these capabilities with adaptive clinical trial designs is fostering an environment in which iterative protocol modifications can enhance efficacy endpoints and safety monitoring in near real time.
Regulatory agencies in multiple regions have signaled willingness to expedite review processes for personalized therapies, reflecting a heightened commitment to fostering innovation. As a result, strategic alliances between biotech pioneers and established pharmaceutical entities are accelerating, uniting deep clinical expertise with cutting-edge platform technologies. These transformative shifts are paving the way for neoantigen vaccines to become integral components of combination regimens and new standard-of-care paradigms.
Analyzing the Far Reaching Cumulative Impact of United States Tariffs Scheduled for 2025 on Neoantigen Vaccine Supply Chains and Pricing Dynamics
The scheduled implementation of new United States tariffs in 2025 is poised to exert material influence on the neoantigen vaccine supply chain. Essential raw materials such as peptide synthesis reagents, nucleic acid precursors, and specialized lipid reagents are predominantly sourced through cross-border supply networks, and increased duties may heighten input costs and complicate procurement timelines.
Manufacturers and contract development organizations are evaluating alternative sourcing strategies, including domestic partnerships and dual sourcing models, to mitigate exposure to elevated import tariffs. In addition, strategic inventory management and advanced demand forecasting are being refined to offset potential lead-time volatility and preserve production continuity.
While pricing pressures may emerge as tariff impacts are assimilated, adaptive pricing strategies and long-term supplier agreements will be critical to preserve margins without compromising affordability. Ultimately, the 2025 tariff adjustments will drive a recalibration of supply chain resilience and cost structures, compelling stakeholders to innovate operational frameworks and reinforce strategic supplier relationships across the vaccine manufacturing continuum.
Uncovering Key Segmentation Insights That Illuminate Patient Targeting Platform Differentiation and Delivery Pathways in Neoantigen Vaccine Markets
The neoantigen cancer vaccine market encompasses multiple layers of segmentation, each shaping product design, clinical application, and commercialization pathways. An antigen classification perspective distinguishes personalized constructs derived from immune escape mutations and somatic mutations, while shared constructs leverage affinity peptides and common tumor mutations to address broader patient populations. Therapeutically, the portfolio spans immune checkpoint blockade strategies-such as CTLA-4 inhibitors and PD-1 inhibitors-and tumor neoantigen modalities segmented into mutated and non-mutated antigens, underscoring the complementary nature of these approaches.
Platform technologies further diversify the landscape, integrating cell-based vaccines with dendritic cell and T cell formats, alongside DNA platforms built on circular DNA constructs and plasmid vaccines. Peptide-based vaccines range from long peptides to synthetic variants, while RNA-based platforms include mRNA vaccines and next-generation RNA innovations. Each platform’s inherent attributes dictate manufacturing complexity, stability profiles, and immunogenic potency.
Delivery mechanisms also play a pivotal role, extending from intradermal and subcutaneous administration to intravenous and emerging oral routes. End-user applications span cancer treatment centers, hospitals, and research institutes, each demanding tailored logistics, cold-chain capabilities, and clinical support services. Understanding these segmentation dimensions is vital to aligning development strategies with clinical and commercial imperatives.
Illuminating Critical Regional Dynamics and Healthcare Ecosystem Drivers Impacting Neoantigen Vaccine Adoption Across Americas EMEA and Asia Pacific
Regional dynamics are shaping the global deployment of neoantigen cancer vaccines, with the Americas leading in clinical trial registrations and innovation hubs. Robust investment in immuno-oncology research, coupled with regulatory frameworks that prioritize personalized medicine, has created a fertile environment for pilot programs and early-stage launches across major markets.
In Europe, Middle East and Africa, diverse regulatory landscapes and reimbursement models require sponsors to adopt nuanced market entry strategies. Harmonization efforts within the European Union are facilitating cross-border clinical studies, while bespoke national initiatives in certain Middle Eastern territories are accelerating adoption among treatment centers focused on precision oncology.
Asia-Pacific markets present a blend of established biotechnology ecosystems and burgeoning biopharmaceutical investment, particularly in regions with strong public-private partnerships and government incentives. Local manufacturing capacity expansion and collaborative clinical networks are reinforcing the region’s role as a critical node in global supply chains, further driving adoption and scaling of neoantigen vaccine solutions.
Examining Key Player Strategies and Collaborative Partnerships Driving Breakthroughs and Commercialization Efforts in Neoantigen Vaccine Research Pipelines
Leading biopharmaceutical companies and specialized biotech innovators are forging strategic alliances to propel neoantigen vaccine programs from bench to bedside. Key players are investing heavily in proprietary target prediction algorithms, advanced vector design and manufacturing scale-up, often partnering with contract development organizations to enhance production agility and cost efficiency.
Collaborations between academic research centers and industry consortia are accelerating translational research, enabling rapid validation of novel antigen candidates and delivery platforms. Mergers and acquisitions activity is also on the rise, with established pharmaceutical firms seeking to bolster immuno-oncology pipelines by integrating cutting-edge neoantigen experts and platform providers into their portfolios.
Competitive differentiation is increasingly grounded in clinical proof-of-concept data, scalable manufacturing infrastructure and robust intellectual property portfolios. Companies that secure strategic licensing agreements for proprietary adjuvants, delivery systems and bioinformatics tools will be best positioned to capture emerging opportunities and meet the diverse needs of oncologists and patients.
Empowering Industry Leaders with Actionable Recommendations to Overcome Development Hurdles Foster Collaboration and Accelerate Neoantigen Vaccine Adoption
To navigate the evolving complexities of neoantigen vaccine development, industry leaders should prioritize the integration of advanced computational modeling with high-throughput immunogenicity assays. Establishing cross-functional teams that bridge bioinformatics, process development and clinical operations will streamline candidate selection and accelerate go-to-clinic timelines.
Building resilient supply chains through strategic alliances with multiple raw material providers and contract manufacturers will mitigate the impact of regulatory shifts and trade policies. Simultaneously, engaging early with regulatory authorities to align on adaptive trial designs and quality benchmarks can reduce approval risks and facilitate scaled manufacturing readiness.
Furthermore, fostering collaborative consortia with academic and patient advocacy groups will amplify clinical trial recruitment and broaden real-world evidence generation. Proactive intellectual property strategies, including co-development agreements and technology licensing, will safeguard innovations while enabling flexible partnership models that maximize market access and patient impact.
Detailing an Integrated Research Methodology Incorporating Primary Interviews Secondary Data Triangulation and Expert Validation for Robust Neoantigen Insights
This research report integrates a multifaceted methodology to ensure depth, accuracy and industry relevance. Primary research was conducted through in-depth interviews with leading oncologists, immunologists, regulatory experts and manufacturing specialists to capture nuanced perspectives on clinical practice, developmental hurdles and future prospects.
Secondary sources including peer-reviewed journals, regulatory filings, conference proceedings and cutting-edge white papers were systematically reviewed to validate emerging trends and technological breakthroughs. Data triangulation was employed to reconcile insights from diverse inputs, enhancing the credibility of thematic analyses.
An expert validation process was undertaken, engaging advisory panels and steering committees to review preliminary findings and identify potential blind spots. This iterative approach ensures that the final deliverable reflects rigorous fact-checking, comprehensive coverage of global developments and actionable intelligence tailored to strategic decision-makers.
Concluding Strategic Imperatives and Outlook on Neoantigen Vaccine Innovations Signifying Future Growth Pathways and Collaborative Research Imperatives
The neoantigen cancer vaccine landscape is on the cusp of groundbreaking advances, driven by synergistic progress in genomics, immunology and biomanufacturing. As development pipelines mature and regulatory pathways evolve, stakeholders must remain agile, leveraging strategic partnerships and robust data analytics to translate scientific innovation into clinical benefit.
Regional adoption patterns and supply chain realignments underscore the importance of versatile operational models and proactive stakeholder engagement. Companies that effectively navigate tariff impacts, optimize manufacturing networks and tailor entry strategies across diverse markets will secure competitive advantage.
Ultimately, the strategic imperatives for neoantigen vaccine stakeholders include fostering cross-sector collaboration, accelerating clinical validation through adaptive design and fortifying intellectual property portfolios. By embracing these imperatives, organizations can position themselves to lead the next wave of personalized immunotherapy breakthroughs and deliver lifesaving treatments to patients worldwide.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Neoantigen Type
Personalized Neoantigens
Immune Escape Mutations
Somatic Mutations
Shared Neoantigens
Affinity Peptides
Common Tumor Mutations
Therapeutic Target
Immune Checkpoint Blockade
CTLA-4 Inhibitors
PD-1 Inhibitors
Tumor Neoantigens
Mutated Neoantigens
Non-Mutated Neoantigens
Vaccine Platform
Cell-Based Vaccines
Dendritic Cell Vaccines
T-Cell Vaccines
DNA-Based Vaccines
Circular DNA Platforms
Plasmid DNA Vaccines
Peptide-Based Vaccines
Long Peptides
Synthetic Peptides
RNA-Based Vaccines
mRNA Vaccines
Next-Gen RNA Platforms
Administration Route
Intradermal
Intravenous
Oral
Subcutaneous
End User
Cancer Treatment Centers
Hospitals
Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Agenus Inc.
AstraZeneca PLC
Avidea Technologies
Ayala Pharmaceuticals, Inc.
BioLineRx Ltd.
BioNTech SE
BioVaxys Technology Corp.
Brightpath Biotherapeutics Co., Ltd.
CureVac N.V.
Elicio Therapeutics Inc
F. Hoffmann-La Roche Ltd.
Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
Genocea Biosciences Inc
GenScript Biotech Corporation
Gilead Sciences, Inc.
Gritstone bio, Inc.
Immunomic Therapeutics, Inc.
ISA Pharmaceuticals B.V.
Medigene AG
Merck & Co., Inc.
Moderna, Inc.
Neophore Limited
Nouscom AG
Nykode Therapeutics ASA
OSE Immunotherapeutics
Takis S.r.l.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI-driven neoantigen identification platforms to enhance personalized vaccine design
- 5.2. Adoption of multiplexed immunopeptidomics to improve neoantigen discovery accuracy in trials
- 5.3. Emergence of mRNA-based neoantigen vaccine platforms advancing rapid manufacturing timelines
- 5.4. Collaboration between biotech and academic centers to accelerate neoantigen clinical validation processes
- 5.5. Increasing investment in personalized neoantigen vaccine programs targeting melanoma and lung cancer
- 5.6. Focus on combining neoantigen vaccines with checkpoint inhibitors to boost therapeutic efficacy in solid tumors
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Neoantigen Cancer Vaccine Market, by Neoantigen Type
- 8.1. Personalized Neoantigens
- 8.1.1. Immune Escape Mutations
- 8.1.2. Somatic Mutations
- 8.2. Shared Neoantigens
- 8.2.1. Affinity Peptides
- 8.2.2. Common Tumor Mutations
- 9. Neoantigen Cancer Vaccine Market, by Therapeutic Target
- 9.1. Immune Checkpoint Blockade
- 9.1.1. CTLA-4 Inhibitors
- 9.1.2. PD-1 Inhibitors
- 9.2. Tumor Neoantigens
- 9.2.1. Mutated Neoantigens
- 9.2.2. Non-Mutated Neoantigens
- 10. Neoantigen Cancer Vaccine Market, by Vaccine Platform
- 10.1. Cell-Based Vaccines
- 10.1.1. Dendritic Cell Vaccines
- 10.1.2. T-Cell Vaccines
- 10.2. DNA-Based Vaccines
- 10.2.1. Circular DNA Platforms
- 10.2.2. Plasmid DNA Vaccines
- 10.3. Peptide-Based Vaccines
- 10.3.1. Long Peptides
- 10.3.2. Synthetic Peptides
- 10.4. RNA-Based Vaccines
- 10.4.1. mRNA Vaccines
- 10.4.2. Next-Gen RNA Platforms
- 11. Neoantigen Cancer Vaccine Market, by Administration Route
- 11.1. Intradermal
- 11.2. Intravenous
- 11.3. Oral
- 11.4. Subcutaneous
- 12. Neoantigen Cancer Vaccine Market, by End User
- 12.1. Cancer Treatment Centers
- 12.2. Hospitals
- 12.3. Research Institutes
- 13. Neoantigen Cancer Vaccine Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Neoantigen Cancer Vaccine Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Neoantigen Cancer Vaccine Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Agenus Inc.
- 16.3.2. AstraZeneca PLC
- 16.3.3. Avidea Technologies
- 16.3.4. Ayala Pharmaceuticals, Inc.
- 16.3.5. BioLineRx Ltd.
- 16.3.6. BioNTech SE
- 16.3.7. BioVaxys Technology Corp.
- 16.3.8. Brightpath Biotherapeutics Co., Ltd.
- 16.3.9. CureVac N.V.
- 16.3.10. Elicio Therapeutics Inc
- 16.3.11. F. Hoffmann-La Roche Ltd.
- 16.3.12. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
- 16.3.13. Genocea Biosciences Inc
- 16.3.14. GenScript Biotech Corporation
- 16.3.15. Gilead Sciences, Inc.
- 16.3.16. Gritstone bio, Inc.
- 16.3.17. Immunomic Therapeutics, Inc.
- 16.3.18. ISA Pharmaceuticals B.V.
- 16.3.19. Medigene AG
- 16.3.20. Merck & Co., Inc.
- 16.3.21. Moderna, Inc.
- 16.3.22. Neophore Limited
- 16.3.23. Nouscom AG
- 16.3.24. Nykode Therapeutics ASA
- 16.3.25. OSE Immunotherapeutics
- 16.3.26. Takis S.r.l.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
